TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05346133

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suicide Prevention Intervention for Adolescents
Description: Suicide Safety Planning Intervention (SPI). SPI is a very brief intervention (20-45 minutes) that provides patients with specific strategies to use to decrease the risk of suicidal behavior. SPI begins with psychoeducation about suicide risk, then the clinician and patient collaboratively create a stepwise plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; and 6) reducing access to means. SPI providers work with caregivers to help them monitor warning signs of suicide risk, encourage the use of the safety plan by their adolescent, and reduce access to lethal means in the home.
Study: NCT05596838

Intervention type: PROCEDURE
Intervention: Intracorneal rings placement
Description: Intracorneal rings placement in keratoconus using laser
Study: NCT04085406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation of the Subgenus Cingulate Cortex
Description: The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation of the Subgenus Cingulate Cortex
Description: The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
Study: NCT05003726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-pharmacological treatment
Description: This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological treatment
Description: This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
Study: NCT05992402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReBOOT program
Description: This is a virtual cognitive intervention led by a clinical neuropsychologist. Participants will attend 2 one-on-one individual sessions and 4 group sessions prior to their epilepsy surgery. Groups will be made up of 3-10 participants. The intervention is designed to provide participants with information about possible changes and/or challenges they may experience after epilepsy surgery, as well as cognitive strategies to implement prior to surgery to increase effectiveness of compensation for any new cognitive difficulties that may be experienced following surgery.
Study: NCT05555407

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scintigraphic gastric emptying scan
Description: Nuclear medicine scan that provides an assessment of gastric motility

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless patch system (WPS)
Description: Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
Study: NCT05696431

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Universal adhesives application
Description: The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: universal adhesive with bioactive properties
Description: The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride-releasing universal adhesive
Description: Fluoride-releasing universal adhesive
Study: NCT04330131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3Ts - Newborn
Description: A video shared with parents/caregivers during a universal screening in hospital mother-baby units. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3Ts - Well Baby
Description: Four videos shared during well child immunization visits at 1-, 2-, 4-, and 6-months in pediatrician offices. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3Ts - Let's Talk!
Description: A series of eight group classes involving education, feedback, and goal setting for parents/caregivers of children age one through three, delivered in a community-based organization. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
Study: NCT06282614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucogyne Ovule
Description: At inclusion visit (V0), the Investigator will ask the subject to use MUCOGYNE® Ovule 2 times a week until symptoms improve during 5 weeks (D35± 3) preferably at bedtime
Study: NCT05327348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ascorbate
Description: Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
Study: NCT05479695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Orthoses and Insoles
Description: Evaluation of scoliosis treatment in people using spinal orthoses and insoles

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Orthoses
Description: Evaluation of scoliosis treatment in people using spinal orthoses
Study: NCT05322681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
Study: NCT06520033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humanoid robot
Description: The humanoid robot will execute an educational hydration plan that will be integrated into the usual dynamics of the residence. In order to increase the fluid intake of the residents, stimulation activities will be proposed that will be carried out by the robot such as reminders, interactive activities and positive reinforcement. It will also allow the daily recording fluid intake of each residents.~This intervention will last two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The center's usual hydration plan
Study: NCT04484077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC
Description: 2x10\^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
Study: NCT06257433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Instructions
Description: Participants will be given cued instructions as to whether they are in a high or low motivation condition
Study: NCT05611008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDSS
Description: A Clinical Decision Support System (CDSS) that calculates older patients' personalized fall risk and provides the GP with advice on how to adjust the patient's medication in order to lower the fall risk.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Portal
Description: A patient portal that provides general information on falls and fall risk to the older patients and helps the patient to prepare for the consultation by filling out a Question Prompt List (QPL). The QPL is a list of possibly relevant questions and topics from which the patient can select those that are important to him/her. These will already be sent to the GP before the consultation takes place.
Study: NCT04822974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood collection
Description: longitudinally collection of blood samples for each patient included.
Study: NCT05160792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure monitoring system under compression bandages on index leg
Description: Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
Study: NCT05513924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months.
Study: NCT06137014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fortified Oral Rehydration Therapy
Description: Oral rehydration solution with reduced glucose and added amino acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Oral Rehydration Therapy
Description: Glucose-based oral rehydration therapy according to World Health Organization guidelines.
Study: NCT05304468

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Patients in experimental group received reduced dose IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Patients in experimental group received reduced dose IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: cisplatin-based induction chemotherapy for two cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: induction chemotherapy
Description: cisplatin-based induction chemotherapy for two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin concurrent chemotherapy
Description: cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin concurrent chemotherapy
Description: cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
Study: NCT05112107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary workshops
Description: Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
Study: NCT04876677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium
Description: Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
Study: NCT05276609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093 (Phase Ia: Dose escalation)
Description: Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093 (Phase Ib: Dose expansion)
Description: IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study: NCT05631431

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curalin
Description: Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals
Study: NCT06213857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property. The first usage of Milk thistle was for its hepatoprotective and antioxidant activities, but in the recent years it has been used to control of immune based murine colitis by healing of bowel histology and reduction of bowel inflammatory cytokines especially TNF-α, interleukin-1β (IL-1β), and nuclear factor κB (NF-κB). Silymarin has anti-viral, immunomodulation, anti-inflammatory effects as well as antioxidant properties by scavenging free radicals and increasing the glutathione concentrations, protective and wound healing effects. It increases the gene expression of antioxidant enzymes and the number of the most important protection mechanisms against free-radicals damage containing superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase.
Study: NCT05743491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YOCAS©®
Description: YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
Study: NCT05760040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vırtual reality
Description: During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
Study: NCT04557891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active LIFUP Treatment
Description: 8 LIFUP Treatments

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LIFUP Treatment
Description: 8 sham LIFUP treatments
Study: NCT05631431

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curalin
Description: Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals
Study: NCT05220254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindCotine's VR app
Description: The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
Study: NCT04875676

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
Study: NCT05419362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN-001
Description: The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg given by intravenous (IV) infusion once every 2 weeks
Study: NCT05185583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
Study: NCT05423626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: technologies of robotic mechanotherapy with FES
Description: Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* exoskeletal robotic device for moving the patient and forming a walking pattern~* a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: technologies of robotic mechanotherapy with FES
Description: Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* exoskeletal robotic device for moving the patient and forming a walking pattern~* a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback virtual reality technologies
Description: Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* hardware and software complex, including a monitor and a personal computer;~* virtual reality helmet;~* sandals with air chambers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback virtual reality technologies
Description: Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* hardware and software complex, including a monitor and a personal computer;~* virtual reality helmet;~* sandals with air chambers.
Study: NCT05344820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art based mandala
Description: To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
Study: NCT05901662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Competence training program
Description: A 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group provided their routine services at senior activity centers.